Castle Biosciences (CSTL) – Decisions Decisions

Castle Biosciences (CSTL) is a market leader in molecular diagnostic testing for multiple types of skin cancer. The company’s tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. KeyBanc analyst Paul Knight highlighted in his initiation note on November 9th that growing revenue at an expected rate of 34-40% the next three years, the company operates at one of the highest industry gross margins at 85.9%.

The company’s “DecisionDx” tests are outlined below:

DecisionDx Melanoma – A test for invasive cutaneous melanoma. DecisionDx®-Melanoma, is a proprietary gene expression profile, or GEP, test that more accurately predicts a patie